Susan Molineaux - Calithera Biosciences Co-Founder, CEO and President and Director
| CALADelisted Stock | USD 0.05 0.00 0.00% |
CEO
Dr. Susan M. Molineaux, Ph.D. serves as President, Chief Executive Officer, CoFounder and Director of Calithera Biosciences Inc. Dr. Molineaux as served as our President, Chief Executive Officer and as a member of our board of directors since she cofounded Calithera in March 2010. Dr. Molineaux cofounded Proteolix, Inc., a biopharmaceutical company, where she served as Chief Scientific Officer from 2003 to 2005, Chief Executive Officer from January 2006 to January 2009 and again as Chief Scientific Officer from February 2009 until Proteolixs acquisition by Onyx Pharmaceuticals, Inc. in November 2009. From 2000 to 2003, Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc., a drug development company. From 1999 to 2000, she served as Vice President of Biology at Praelux, Inc., a biopharmaceutical company, and from 1994 through 1999, she served as Vice President of Drug Development at Praecis Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 until 1994, she was a scientist in the Immunology group at Merck Co. Dr. Molineaux currently serves as a member of the board of directors of Geron Corporationrationration, Theravance Biopharma, Inc. and Smith College, and is a Scientific Advisor for Lightstone Ventures since 2010.
| Age | 69 |
| Tenure | 14 years |
| Professional Marks | Ph.D |
| Phone | 650 870-1000 |
| Web | www.calithera.com |
Calithera Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.5629) % which means that it has lost $0.5629 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1414) %, meaning that it created substantial loss on money invested by shareholders. Calithera Biosciences' management efficiency ratios could be used to measure how well Calithera Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Calithera Biosciences currently holds 1.67 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Calithera Biosciences has a current ratio of 4.72, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Calithera Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Calithera Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Calithera Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Calithera to invest in growth at high rates of return. When we think about Calithera Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 11 records | CEO Age | ||
| Michael Raab | Ardelyx | 59 | |
| Allen Baharaff | Galmed Pharmaceuticals | 59 | |
| Frank BeduAddo | PDS Biotechnology Corp | 59 | |
| CFA III | Checkpoint Therapeutics | 48 | |
| Stephen JD | Pieris Pharmaceuticals | 48 | |
| Adrian Rawcliffe | Adaptimmune Therapeutics Plc | 52 | |
| Vishwas MBA | Abeona Therapeutics | 48 | |
| Adi Hoess | Affimed NV | 63 | |
| Laurent Fischer | Adverum Biotechnologies | 60 | |
| Daniel Paterson | Verastem | 63 | |
| Denise ScotsKnight | Mereo BioPharma Group | 65 | |
Management Performance
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.56 |
Calithera Biosciences Leadership Team
Elected by the shareholders, the Calithera Biosciences' board of directors comprises two types of representatives: Calithera Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Calithera. The board's role is to monitor Calithera Biosciences' management team and ensure that shareholders' interests are well served. Calithera Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Calithera Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Allison Dillon, VP Strategy | ||
| Susan Demo, VP Operations | ||
| Stephanie Wong, Chief Accounting Officer, Vice President - Finance | ||
| Frank Parlati, VP Research | ||
| Eric Sjogren, Sr. VP of Drug Discovery | ||
| Emil MD, Chief Officer | ||
| Christopher Molineaux, Sr. VP of Devel. | ||
| Susan Molineaux, Co-Founder, CEO and President and Director |
Calithera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Calithera Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | (1.1 M) | ||||
| Shares Outstanding | 4.87 M | ||||
| Shares Owned By Insiders | 1.07 % | ||||
| Shares Owned By Institutions | 26.76 % | ||||
| Number Of Shares Shorted | 417.28 K | ||||
| Price To Earning | (14.08) X | ||||
| Price To Book | 1.86 X | ||||
| Price To Sales | 1.71 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Calithera Pink Sheet
If you are still planning to invest in Calithera Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calithera Biosciences' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Directory Find actively traded commodities issued by global exchanges |